These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 28875236)

  • 1. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
    Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
    Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
    Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
    Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of bisphosphonates in women: when to use and when to stop.
    Gatti D; Adami S; Viapiana O; Rossini M
    Expert Opin Pharmacother; 2015; 16(16):2409-21. PubMed ID: 26357942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
    Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
    JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.
    Adams AL; Adams JL; Raebel MA; Tang BT; Kuntz JL; Vijayadeva V; McGlynn EA; Gozansky WS
    J Bone Miner Res; 2018 Jul; 33(7):1252-1259. PubMed ID: 29529334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR; Lee J
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
    Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
    Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.